I got my latest test results and it looks like I am dancing around between detectable and undetectable on the PCR. My last one was negative, this one was slightly positive. My thinking all along was that the last one might have been a false negative. Fortunately my FISH went back to negative. My last FISH had shown 1 out of 500 positive, which was largely considered to be a false positive. The FISH was negative this time around so I think I am done with that.
I'm having trouble really understanding how to calculate my log reduction given the way the lab is reporting the results. They are not using international scale and basically they are giving me the percentage of BCR-ABL detected when comparing to a control line. When it went negative on the last one, I just let it go as it didn't seem worth while trying to figure out how to calculate the true log reduction when it was negative, but now that it ticked back up a little, I am trying to really get a clear picture on what the trajectory has been and how to properly calculate the log reduction. Overall the trend is downward so that is good, but I would just like to understand how to really calculate this once and for all, now that I have a good sample set.
So here is the test history with the latest being at the bottom, with the exact verbiage they use on the report.
Trey, Phil, Gunner - anyone up for giving another math lesson?
Thanks
7/7/2010
Specimens submitted: Blood(Paxgene)
Test Performed: Quantitative RT-PCR for detection of minimum residual disease.
RNA quality: good
Methodology: Real-Time Reverse Transcription Polmerase Chain Reaction using TaqMan assay Design
Primers: TBP (control) BCR, ABL
Diagnostic Interpretation:Positive for BCR-ABL (P210) transcripts, indicating presence of a CML-type Philadelphia chromosome, consistent with CML or a subset of ALL.
After normalization (comparison) with positive control cell line K562, the level of positivity for BCR-ABL is approximately 1.2%
10/25/2010
Specimens submitted: Blood(Paxgene)
Test Performed: Quantitative RT-PCR for detection of minimum residual disease.
RNA quality: good
Methodology: Real-Time Reverse Transcription Polmerase Chain Reaction using TaqMan assay Design
Primers: TBP (control) BCR, ABL
Diagnostic Interpretation:Positive for BCR-ABL (P210) transcripts, indicating presence of a CML-type Philadelphia chromosome, consistent with CML or a subset of ALL.
After normalization (comparison) with positive control cell line K562, the level of positivity for BCR-ABL is approximately .25%
12/13/2010
Specimens submitted: Bone Marrow
Test Performed: Quantitative RT-PCR for detection of minimum residual disease.
RNA quality: good
Methodology: Real-Time Reverse Transcription Polmerase Chain Reaction using TaqMan assay Design
Primers: TBP (control) BCR, ABL
Diagnostic Interpretation:Positive for BCR-ABL (P210) transcripts, indicating presence of a CML-type Philadelphia chromosome, consistent with CML or a subset of ALL.
After normalization (comparison) with positive control cell line K562, the level of positivity for BCR-ABL is approximately .367%
3/14/2011
Specimens submitted: Blood(Paxgene)
Test Performed: Quantitative RT-PCR for detection of minimum residual disease.
RNA quality: good
Methodology: Real-Time Reverse Transcription Polmerase Chain Reaction using TaqMan assay Design
Primers: TBP (control) BCR, ABL
Diagnostic Interpretation:Positive for BCR-ABL (P210) transcripts, indicating presence of a CML-type Philadelphia chromosome, consistent with CML or a subset of ALL.
After normalization (comparison) with positive control cell line K562, the level of positivity for BCR-ABL is approximately .0081%
6/13/2011
Specimens submitted: Blood(Paxgene)
Test Performed: Quantitative RT-PCR for detection of minimum residual disease.
RNA quality: good
Methodology: Real-Time Reverse Transcription Polmerase Chain Reaction using TaqMan assay Design
Primers: TBP (control) BCR, ABL
Diagnostic Interpretation: Negative for BCR-ABL (P210 type) RNA transcripts, indicating absence of cells with CML-type Philadelphia chromosome
Diagnostic sensitivity: This assay is negative in <1% of CML cases.
Technical sensitivity: A clonal cell population <0.003% may not be detected by this assay based on the RNA quality of the sample
9/19/2011
Specimens submitted: Blood(Paxgene)
Test Performed: Quantitative RT-PCR for detection of minimum residual disease.
RNA quality: good
Methodology: Real-Time Reverse Transcription Polmerase Chain Reaction using TaqMan assay Design
Primers: TBP (control) BCR, ABL
Diagnostic Interpretation:Positive for BCR-ABL (P210) transcripts, indicating presence of a CML-type Philadelphia chromosome, consistent with CML or a subset of ALL.
After normalization (comparison) with positive control cell line K562, the level of positivity for BCR-ABL is approximately .00084%